Rubius Therapeutics Management
Management criteria checks 0/4
We currently do not have sufficient information about the CEO.
Key information
Craig Jalbert
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | n/a |
| Management average tenure | no data |
| Board average tenure | 2.7yrs |
Recent management updates
Recent updates
Rubius Therapeutics GAAP EPS of -$0.49 beats by $0.03
Aug 09Rubius: Poor Data, Punishing Environment, Beaten Stock
Jun 19Rubius Looks Attractive Before AACR Data Readout
Mar 21Are Rubius Therapeutics, Inc. (NASDAQ:RUBY) Investors Paying Above The Intrinsic Value?
Oct 28
Our Read On Rubius Therapeutics
Jul 11Rubius Therapeutics EPS beats by $0.02
May 10Have Insiders Been Buying Rubius Therapeutics, Inc. (NASDAQ:RUBY) Shares?
Feb 25Rubius Therapeutics (RUBY) Presents At 39th Annual Healthcare Conference - Slideshow
Jan 14Rubius Therapeutics EPS misses by $0.01
Nov 09Rubius Therapeutics' RTX-321 shows dual mechanism of action in HPV-positive cancers
Oct 28CEO
Craig Jalbert (61 yo)
less than a year
Tenure
Mr. Craig R. Jalbert, CIRA, serves as President, Corporate Secretary, Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer at Evelo Biosciences, Inc. since November 21,...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | less than a year | no data | no data | |
| Independent Director | 9.1yrs | US$421.66k | no data | |
| Member of Scientific Advisory Board | 9.1yrs | US$850.74k | no data | |
| Scientific Advisory Board | 5.9yrs | US$24.00k | no data | |
| Member of Scientific Advisory Board | 2.7yrs | no data | no data | |
| Member of Scientific Advisory Board | 2.7yrs | no data | no data | |
| Director | 1.5yrs | no data | no data | |
| Independent Director | 6yrs | US$426.66k | no data | |
| Member of Scientific Advisory Board | 4yrs | US$2.84m | no data | |
| Member of Scientific Advisory Board | 2.7yrs | no data | no data | |
| Member of Scientific Advisory Board | 2.7yrs | no data | no data |
2.7yrs
Average Tenure
68yo
Average Age
Experienced Board: RUBY's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/01/03 01:20 |
| End of Day Share Price | 2023/12/29 00:00 |
| Earnings | 2022/12/31 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Rubius Therapeutics, Inc. is covered by 5 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Schmidt | Guggenheim Securities, LLC |
| Andrew Fein | H.C. Wainwright & Co. |
| Michael Yee | Jefferies LLC |